Test 2

Please select your preferred language.

請選擇你慣用的語言。

请选择你惯用的语言。

English
中文简体
台灣繁體
香港繁體

登入

记住我

初到 Fridae?

Fridae Mobile

Advertisement
Highlights

More About Us

Fresh : Blogs

Recent Blog Posts

kylie1

The SARM1 targeting therapeutics market is projected to grow at a CAGR of 102.1%, during the period 2033-2040, claims Roots Analysis

kylie1 - 11个小时前

SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share

 

Roots Analysis has announced the addition of “SARM1 Inhibitors Therapeutics Market, 2022 – 2040 report to its list of offerings.

 

Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide. With the ongoing pace of innovation in this field, increasing R&D activity and promising pre-clinical data, several promising leads are anticipated to be commercially launched over the coming decade and SARM1 targeting therapeutics market is anticipated to witness substantial growth in the mid to long-term. 

 

Key Market Insights  

 

Presently, several SARM1 targeting therapy candidates are being developed by various industry players

About 65% of the pipeline candidates are currently being evaluated in the preclinical stages of development, followed by those currently in the discovery stage (35%). Further, it is worth mentioning that close to 85% of the SARM1 inhibitors are small molecules.

 

Currently, a number of companies claim to be engaged in the development of SARM1 inhibitors

The SARM1 inhibitors market is dominated by the presence of large companies (81%), followed by small players (19%). In addition, around 20% of the players were established post-2010.

 

120+ articles related to SARM1 inhibitors have been published between 2011 and 2022

Majority (81%) of the articles published in this domain were research papers, followed by review papers (12%). It is important to note that more than 70% of the total number of articles were published post-2018.

 

Over 30 grants have been awarded for research related to SARM1 inhibitors, since 2014

Close to 40% of the total amount was awarded under the R01 mechanism (which supports research projects). Further, genetics and neurology emerged as the key research departments, having received 34% of the total grants, each.

 

70+ patents related to SARM1 targeting therapeutics have been filed / granted till 2022

Over the years, the number of patents filed for SARM1 inhibitors has increased gradually; majority of the patents have been filed / granted in 2021. Most of the patents in this domain are patent applications (96%), followed by granted patents (3%).

 

North America is anticipated to capture more than 65% share of the market, by 2040

By 2040, the market revenues are likely to be driven by the sales of small molecules (95%) being developed as SARM1 inhibitors. Further, sales of therapeutics targeting multiple sclerosis are likely to contribute to a majority share (~40%) of revenues, in the long term.

 

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/sarm1-inhibitors-market/request-sample.html

 

Key Questions Answered

§  Who are the leading players engaged in the development of SARM1 targeting therapeutics?

§  What is the evolving trend of publications focused on SARM1 targeting therapeutics?

§  How is the intellectual property landscape in this field likely to evolve in the foreseen future?

§  What are the recent developments and strategic initiatives undertaken by players engaged in this market space related to the research and development of SARM1 targeting therapeutics?

§  What are the key value drivers that are likely to influence the evolution of this upcoming market?

§  How is the current and future market opportunity likely to be distributed across key market segments?

 

The financial opportunity within the SARM1 targeting therapeutics market has been analyzed across the following segments:

 

§  Type of Molecule

§  Small Molecules

§  Biologics

 

§  Target Indication

§  Multiple Sclerosis

§  Peripheral, Central and Ocular Nervous System Disorders

§  Peripheral Neuropathies

§  Glaucoma

§  Amyotrophic Lateral Sclerosis

 

§  Drug Developers

§  Company 1

§  Company 2

§  Company 3

 

§  Drug Candidates

§  Drug Candidate 1

§  Drug Candidate 2

§  Drug Candidate 3

§  Drug Candidate 4

§  Drug Candidate 5

§  Drug Candidate 6

 

§  Key Geographies 

§  North America

§  Europe

 

The research includes detailed profiles of key players (listed below); featuring an overview of the company, financial information (if available), details related to its product portfolio, patent portfolio, recent developments (including partnerships and collaborations) and an informed future outlook.

§  Disarm Therapeutics

§  Nura Bio

§  Washington University

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/sarm1-inhibitors-market.html

or email sales@rootsanalysis.com

 

You may also be interested in the following titles:

1.       RNAi Market: Therapeutics and Technologies (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition): Industry Trends and Global Forecasts, 2022-2035

2.       Global Therapeutic Vaccines Market: Industry Trends and Global Forecasts, 2022-2035

 

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

 

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com

 

kylie1

AI-BASED DIGITAL PATHOLOGY GAINS INTEREST DUE TO AUTOMATION, DIGITIZATION OF HEALTHCARE, SHORTAGE OF PATHOLOGISTS, AND INCREASED DEMAND FOR PATHOLOGY SERVICES

kylie1 - 3天内

In recent years, advancements in technology and emphasis on precision medicine have recently paved the path for the development of artificial intelligence (AI) based digital pathology techniques for quantitative and qualitative assessment of samples.

Specifically, the process of AI-based digital pathology allows scanning of slides via computer monitors, by replacing the conventional microscopic approaches. Further, by converting glass slides to images, samples can be transmitted from diagnostic centers to pathologists within a fraction of time. Considering the rising popularity and demand for such solutions in the healthcare and research industry, and the ongoing efforts of AI-powered digital pathology solution providers / AI pathology solution providers to further improve / expand their respective portfolios, we believe that the AI-based digital pathology market /  AI Pathology Market is likely to evolve at a steady pace, till 2035.

 

To request a sample copy / brochure of this report, please visit this

https://www.rootsanalysis.com/reports/ai-based-digital-pathology-market/request-sample.html

 

The steps involved in the usual workflow of AI-based digital pathology process.

 

§  Preparation of Tissue Sample: This process is very similar to the conventional approach. A pathologist examines a biopsy to determine its color, size and consistency. At this point, the specialist can detect symptoms of malignancy and select which areas of a specimen should be inspected under the microscope. Further, the chosen region is prepared by following multi-step processes, such as treatment of the tissue with chemicals in order to maintain its structure, mounting the specimen on a glass slide, staining to improve contrast and protecting the tissue with coverslips.

 

§  Converting into Virtual Sample / Whole slide imaging (WSI): WSI or virtual microscopy is a technique that is used to enable digital pathology. Its central component, which is a WSI scanner, captures a picture of the glass slide and generates a precise electronic replica known as a virtual slide. It is worth noting that virtual slides, unlike glass slides, are easy to replicate, save, categorize and distribute. Furthermore, they may be linked to electronic health records, thereby, providing a complete picture of a patient's health.

 

§  Saving a Virtual Slide: The scanner pre-processes the virtual slide automatically and stores it to on-premises or cloud storage. In order to minimize the file size, a compression approach is frequently employed before saving the slide.

 

§  Viewing and Editing of Slide: In the digital process, instead of using a traditional microscope, a pathologist uses a computer display to analyze enlarged tissue samples. A slide viewing and management software is used to zoom out a tissue segment and observe its smallest features. In addition, this software allows the pathologist to view the slide from different angles, add annotations and even compare multiple images at one time.

 

§  Sharing Data: Using specialized digital pathology software applications, slides are converted to an electronic format, thereby, allowing them to be exchanged using the internet. These slides can be shared to gain a second opinion, as well as with patients, research facilities and other stakeholders.

 

§  Reporting Results: Some image viewing systems provide reporting capabilities. However, this work is often accomplished by enabling interaction with the laboratory information or laboratory information management system (LIS/LIMS) and hospital information system (HIS).

 

The digital revolution of pathology is projected to accelerate in the coming years, considering multiple growth drivers, including growing number of laboratories adopting high throughput digital scanning and software technologies to assist diagnostic practice. In addition, factors, including shortage of skilled pathologists in remote areas, increasing pathology workloads due to ageing populations, higher rate of cancer screening programs, rising complexity of pathology testing and time constraints, and requirement for pathology labs to outsource expertise in the field, also contributes significantly towards the need for AI-based digital pathology solutions.

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/ai-based-digital-pathology-market.html or email sales@rootsanalysis.com

 

You may also be interested in the following titles:

1.      Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035

2.      4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035

 

 

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

                       

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

 

 

kylie1

The smart pharmaceutical and healthcare labels market is anticipated to grow at a CAGR of 16%, till 2035, claims Roots Analysis

kylie1 - 4天内

In order to overcome the limitations and challenges related to counterfeit drugs, researchers and industry stakeholders are gradually adopting smart pharmaceutical and healthcare labels, which offer multiple benefits over conventional labels.

Roots Analysis has announced the addition of “Smart Pharmaceutical and Healthcare Labels Market, 2022-2035” report to its list of offerings.

 

A smart label comprises of printed information, a bar code identifier and a small transponder. This transponder contains a processing chip and an antenna that allows physical objects to communicate with the tag reader (for instance, RFID reader). Smart labels offer several benefits, such as tracing and tracking products in a supply chain, tamper proofing, as well as discouraging counterfeiters from packaging fake drugs. In this context, it is worth mentioning that smart labelling technology can potentially save USD 0.8 - 1.5 million per year, per company, through their applications in inventory management.

 

 

Key Market Insights

 

More than 90 companies claim to offer smart pharmaceutical and healthcare labels, globally

This segment of the industry is dominated by the presence of mid-sized (51-500 employees) and small (less than 50 employees) players, which collectively represent more than 75% of the total smart label providers in pharmaceutical and healthcare sectors. Further, ~20% of firms were established post-2010.

 

400+ patents related to smart pharmaceutical and healthcare labels were filed / granted, since 2015

Based on intellectual property distribution across the world, R&D activity related to smart pharmaceutical and healthcare labels is largely concentrated in North America (over 65%), followed by Europe (10%). In addition, most of the patents have been granted patent (55%), followed by patent applications (44%).

 

Partnership activity in this domain has increased at a significant pace, between 2018 and 2022

The recent partnerships trend in this market indicates the growing interest of industry stakeholders. It is worth highlighting that majority of the deals were service alliances, representing around 41% of the total number of partnerships signed in the given time period.

 

North America and Europe are anticipated to capture over 65% of the market share by 2035

The markets in Asia-Pacific and Latin America are anticipated to grow at a relatively faster pace. In the long-term, the aforementioned regions are expected to collectively represent 33% of the total market share. In addition, RFID based smart labels are likely to capture more than 75% of the market share in 2035.

 

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/smart-labels-market/request-sample.html

 

Key Questions Answered

§  Who are the leading players engaged in the development of smart pharmaceutical and healthcare labels?

§  What is the relative competitiveness of different smart pharmaceutical and healthcare labels providers?

§  Which types of partnership models are most commonly being adopted by stakeholders engaged in this domain?

§  What are the key strategies that can be implemented by emerging players / start-ups to enter the highly competitive market for smart labels for the healthcare sector?

§  Which companies are actively filing patents to drive innovation in the field of smart pharmaceutical and healthcare labels?

§  What are the key challenges within the smart pharmaceutical and healthcare labels market?

§  What is the current / likely future market size of smart pharmaceutical and healthcare labels?

 

 

The financial opportunity within the smart pharmaceutical and healthcare labels market has been analyzed across the following segments:

 

§  Type of Technology

§  RFID

§  NFC

§  Other Technologies

 

§  Type of packaging

§  Primary Packaging

§  Secondary Packaging

 

§  Type of Primary Packaging

§  Vials

§  Syringes

§  Cartridges

§  Ampoules

§  Bottles

§  Blister Packs

 

§  Type of Secondary Packaging

§  Boxes

§  Cartons

§  Pouches

 

§  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific

§  MENA

§  Latin America

 

The report includes detailed profiles of key players (listed below) engaged in providing smart pharmaceutical and healthcare labels; each profile features an overview of the developer, details related to smart labels focused product portfolio, recent developments and an informed future outlook:

§  CCL Industries

§  Schreiner

§  Datalogic

§  Tadbik

§  SATO

§  Invengo

§  Intellhydro Technology

§  RFiD Discovery

§  ID Tech Solutions

 

For additional details, please visit https://www.rootsanalysis.com/reports/smart-labels-market.html or email sales@rootsanalysis.com

 

You may also be interested in the following titles:

1.     Pharmaceutical Secondary Packaging Market: Industry Trends and Global Forecast, 2022-2035

2.     AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

 

Contact:

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

kylie1

The liposome development and manufacturing services market is anticipated to grow at a CAGR of nearly 10% till 2035, claims Roots Analysis

kylie1 - 一个星期前

 

Driven by the development of advanced methods for preparation and characterization of liposomes, and the application of these molecules in therapeutics and diagnostics, the demand for liposomes is expected to rise in the coming years.

 

London

 

Roots Analysis has announced the addition of “Liposome Manufacturing Market, 2022-2035” report to its list of offerings.

 

Despite the growing interest in liposome-based therapeutics and diagnostics, the development and manufacturing of liposomes is associated with several challenges, including complex manufacturing processes, huge capital investments, inadequate clinical grade production and GMP compliant industrial scale-up, lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. In order to deal with the aforementioned challenges, a number of pharmaceutical companies have demonstrated the preference to outsource their respective liposome development and manufacturing operations to specialized service providers.

 

Key Market Insights

 

More than 70 companies are currently offering services related to liposome development and manufacturing, globally 

Majority (74%) of the service providers offer formulation development services for liposomes. This is followed by players offering analytical method development (65%), liposome contract manufacturing (64%), and process development (61%) services.

 

Close to 6,100 articles focused on liposomes, have been published in reputed scientific journals, since 2017

More than 50% of the articles focused on liposomes were published post-2019. Popular journals that have published multiple articles include International Journal of Pharmaceutics, Journal of Controlled Release, and Pharmaceutics.

 

More than 800 clinical trials have been registered for the evaluation of liposome-based therapeutics, worldwide

The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 17%, during the period 2017-2021. Of the total number of trials registered, 60% have already been completed, while 26% of the studies are actively recruiting participants. 

 

Nearly 700 patents related to liposomes have been filed / granted, since 2017

Owing to the increase in research and development efforts led by several industry and non-industry players engaged in this domain, close to 55% of patent applications have been filed post-2016. It is worth noting that 61% patents related to liposomes were filed / granted in the US alone.

 

Over 110 global events related to liposomes were organized in the past couple of years

Majority (63%) of the events related to liposomes, were organized virtually in order to comply with the guidelines in the ongoing COVID-19 pandemic. Further, the agendas of the events organized post-2020 include discussions on the applications, and recent advancements in technologies associated with liposomes.

 

Go / No-Go framework can be used to assist players in the crucial outsourcing decision-making process

The framework enables evaluation of the current capabilities of liposome-based therapeutic developers, based on 4+ parameters, including trial phase, target therapeutic area, location of trial(s), patient enrollment and willingness to outsource.

 

North America is anticipated to capture over 40% of the global market share for liposome development and manufacturing services, by 2035 

In terms of type of product formulation, the therapeutic formulations of liposomes (71%) are anticipated to capture the highest share, this trend is unlikely to change in the foreseen future. Further, based on end users, majority of the revenue share (76%) of the overall market is likely to be driven by pharmaceutical and biotechnology industry, by 2035. 

 

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/liposome-manufacturing-market/request-sample.html

                                                                                     

Key Questions Answered

§  Who are the key players offering liposome development and manufacturing services?

§  What is the evolving trend of publications focused on liposomes?

§  How many patents, related to liposomes, have been filed / granted in the past few years?

§  Which companies are actively involved in conducting clinical trials for liposomes?

§  What are the key agenda items being discussed in various global events / conferences related to liposomes?

§  Which factors are likely to influence the decision of liposome manufacturing being done in-house or outsourced?

§  How is the current and future market opportunity related to liposome development and manufacturing services, likely to be distributed across key market segments?

 

The financial opportunity within the liposome development and manufacturing services market has been analyzed across the following segments:

§  Type of Product Formulation

§  Therapeutic

§  Nutraceutical

 

§  Scale of Operation

§  Discovery / Research

§  Preclinical

§  Clinical

§  Commercial

 

§  End User

§  Pharmaceutical and Biotechnology Industry

§  Cosmetic Industry

§  Food Industry

§  Agricultural Industry

§  Academics

§  Other Industries

 

§  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific

§  Middle East and North Africa

§  Latin America

 

The research also includes detailed profiles of the key players (listed below) offering services for liposome development and manufacturing; each profile features an overview of the company, its financial information (if available), details on service portfolio, recent developments and an informed future outlook.

§  Baxter BioPharma Solutions

§  Charles River Laboratories

§  Evonik

§  Fresenius Kabi

§  Fujifilm

§  GEA

§  Intertek

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/liposome-manufacturing-market.html

or email sales@rootsanalysis.com

                                                                                                                                               

You may also be interested in the following titles:

1.     Biologics Fill Finish Services Market (3rd Edition), 2022-2035

2.     Bioavailability Enhancement Technologies and Services Market, 2022-2035

 

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

                       

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com

 

IndyBear69

Kiss me

IndyBear69 - 一个星期前

Don't kiss me like we are married, kiss me like we are lovers

pettytriff

你好

pettytriff - 一个星期前

我是來找另一半的 我喜歡亞洲、優雅、英俊的男性。 讓我們互相了解一下。 我來自羅馬尼亞的克盧日納波卡。 我知道我離你很遠。 而且我也有一個缺點,我只會說羅馬尼亞語。 但我還是想完成我的夢想。

hugu

萍聚

hugu - 2个星期前
Sexagenarian

Life Is A Journey

Sexagenarian - 2个星期前

“When you were born, you were crying and everyone else was smiling. Live your life so at the end, your're the one who is smiling and everyone else is crying.”

Sexagenarian

Getting Old

Sexagenarian - 2个星期前

"You have to embrace getting old. Life is precious and when you've lost a lot of people, you realize that each day is a gift."

Lizbo

Nerve wracking day😅

Lizbo - 2个星期前

Why?

Cos its meet her parents day... was really nervous. All went well.

 

Lizbo

The journey 💑

Lizbo - 2个星期前

You said -let's go for late night supper at Macdonalds again...

You like to eat Mac? I asked. 

Nope- you said..

I just enjoy our journey back home...with you holding my hands and we chatting casually... very simple but i loved it💕

james831aj

Bidding farewell to 2022

james831aj - 3个星期前

31 December 2022 Sunny morning 07:58a.m.

In a blink, 2022 passed through the passage of time.

It has been a good year, though I wish it could be better.

I spent quality time with my mum. This is the best thing I have gained in 2022.

Still alone; did not meet any guy or have sex with anyone. I haven't have sex since 2018 at least. 

What is there for me in 2023? I pray for a healthy, smooth-going, joyful, peaceful year. It will be a bonus if I meet someone in 2023.

Happy New Year to all my Fridae friends.

Thank you for walking this journey with me for 2022.

 

 

BB23

Ed Sheeran - Shivers

BB23 - 4个星期前
I took an arrow to the heart
I never kissed a mouth that tastes like yours
Strawberries and somethin' more
Ooh yeah, I want it all
Lipstick on my guitar (ooh)
Fill up the engine, we can drive real far
Go dancin' underneath the stars
Ooh yeah, I want it all
Mm, you got me feelin' like
I wanna be that guy, I wanna kiss your eyes
I wanna drink that smile, I wanna feel like I'm
Like my soul's on fire, I wanna stay up all day and all night
Yeah, you got me singin' like
Ooh, I love it when you do it like that
And when you're close up, give me the shivers
Oh baby, you wanna dance 'til the sunlight cracks
And when they say the party's over, then we'll bring it right back
And we'll say, ooh, I love it when you do it like that
And when you're close up, give me the shivers
Oh baby, you wanna dance 'til the sunlight cracks
And when they say the party's over, then we'll bring it right back
Into the car
On the backseat in the moonlit dark
Wrap me up between your legs and arms
Ooh, I can't get enough
You know you could tear me apart (ooh)
Put me back together and take my heart
I never thought that I could love this hard
Ooh, I can't get enough
Mm, you got me feeling like
I wanna be that guy, I wanna kiss your eyes
I wanna drink that smile, I wanna feel like I'm
Like my soul's on fire, I wanna stay up all day and all night
Yeah, you got me singin' like
Ooh, I love it when you do it like that
And when you're close up, give me the shivers
Oh baby, you wanna dance 'til the sunlight cracks
And when they say the party's over, then we'll bring it right back
And we'll say, ooh, I love it when you do it like that
And when you're close up, give me the shivers
Oh baby, you wanna dance 'til the sunlight cracks
And when they say the party's over, then we'll bring it right back
Baby, you burn so hot
You make me shiver with the fire you got
This thing we started, I don't want it to stop
You know you make me shiver-er-er
Baby, you burn so hot
You make me shiver with the fire you got
This thing we started, I don't want it to stop
You know you make me shiver
Yeah, you got me singin' like
Ooh, I love it when you do it like that
And when you're close up, give me the shivers
Oh baby, you wanna dance 'til the sunlight cracks
And when they say the party's over, then we'll bring it right back (oh no)
And we'll say, ooh, I love it when you do it like that
And when you're close up, give me the shivers
Oh baby, you wanna dance 'til the sunlight cracks
And when they say the party's over, then we'll bring it right back, hey
james831aj

Another lonely Christmas has passed

james831aj - 一个月前

26 Dec 2022 Monday Sunny 12:41 p.m.

Another Christmas has passed. Still alone. The only companion are my mum and the lighting on the streets. Otherwise, Christmas is just like any day.

I feel sad, ever time when there is festive season. I do appreciate celebrating the festive seasons with my mother, but somehow, I feel empty in my my heart. I see posts in media, couples together, spending the festive season together. I am envious. How I wish, i wake up on Christmas day, naked and cuddling with a man. Perhaps we wake up together and make love to start the day. How nice and sweet feeling.

Christmas has passed. Time to welcome the new year. Hope 2023 will be a good year.

Lizbo

Keys to my heart ❤ 1st Christmas

Lizbo - 一个月前

You told me the key chains you buy for us will be the key chain for our future house keys....

Had a simple celebration for Maxwell's birthday and spend our 1st Christmas together... Nothing grand.. jus simple cozy time together...

 

hksar

Christmas Eve 2022

hksar - 一个月前

"也许一个勇敢的决定 能换两个重生的约定
“我们到了站” 这一站叫终于"

 

终于结束的起点 - 五月天

diunilaomu

想要寻求一个温柔有暴力的情人来捅我的屁眼,好痒耶,约电+86 18034133479

diunilaomu - 一个月前

想要寻求一个温柔有暴力的情人来捅我的屁眼,好痒耶,约电+86 18034133479

Lizbo

Back to basic ( I send her home💕)

Lizbo - 一个月前

I walked u home from bus stop.. we were holding hands n chatting casually. 

Lift is here, we went in together.  Reached ur floor, we walked out and give each other a hug and i give u a peck on ur forehead. 

You said: careful on ur way home and give me another hug💕 Miss u already.. 

Very simple moments but im feeling very blessed. 

 

 

 

smith4u

Single-Use Downstream Bioprocessing Technology Market Size and Forecast by 2035

smith4u - 一个月前

Single-use Technology: An Emerging Technology

Single-Use Downstream Bioprocessing Technology Market: With the increasing global population, the incidence rates of several chronic disease indications, are on the rise. This has led to a rise in the demand for effective treatment options for patients suffering from these diseases. In order to improve the quality of life for these patients, several companies emerged for the development of best possible treatment options. One such option is novel biologics / therapies.

For which, companies require efficient, high yielding, sterile bioprocessing systems. As a result of which, innovators came up with the idea of single-use upstream and downstream technologies.  These technologies has the potential to overcome various challenges associated with the stainless-steel equipment.

The development of single-use downstream equipment started nearly 40 years ago in 1980s with the manufacturing of small process-scale plastic filter capsules replacing stainless-filter housing assemblies. In addition to being user-friendly and convenient for biopharmaceutical manufacturers, single-use technology offer cost saving potential, which in return assists in lowering the cost of manufactured biologics. Further, it lowered costs associated with its facility installation by minimizing the contamination risk to a great extent.,

Get Detailed Report: https://www.rootsanalysis.com/reports/single-use-downstream-bioprocessing-market.html

Single-use Technology For Efficient  Bioprocessing

The increased acceptance and approval of various biologics is a positive sign that novel cures and treatment options for a variety of ailments and diseases afflicting today's global population are on the way.

As a result of the effectiveness of these initiatives, stakeholders have decided to modernize the traditional biologics manufacturing technologies. Given the inherent benefits of single-use downstream equipment, a number of players have launched their proprietary products for use at different scale and mode of operation. The demand for more productivity and flexibility, greater profitability, and faster time to market are some of the factors pushing the replacement of traditional stainless steel equipment with single-use technology as the biopharmaceutical industry evolve.

These technologies have become widely utilized in the bioprocessing sector for R&D and clinical production in recent years, particularly for upstream bioproduction, followed by downstream bioprocessing attempting to keep up with the rising single-use upstream production and utilization.

Because of multiple advantages and benefits over traditional stainless steel technologies, such as reduced CO2 emission, lower project lead time, reduction in total labor and risk associated with cross contamination, single-use technologies have increasingly become an essential tool in the development of various biotechnological processes.

Equipment launched by several developers in the field of single-use downstream bioprocessing includes disposable chromatography systems, disposable filtration systems, disposable sampling systems, disposable connectors and disposable centrifugation systems. Apart from providing scalable downstream bioprocessing equipment, few developers have incorporated automation, resulting in a user-friendly device.

Further, it is worth mentioning that several developers have made significant efforts in developing novel single-use downstream bioprocessing equipment, paving the way for new generation of downstream bioprocessing devices. The field is presently witnessing several innovations, such as visual data display, remote accessibility, data processing capability, Built-in System Control Sensors, Irradiation (Gamma or x-ray), Provision for Alarms / Alerts and input / output compatibility. In this context, it is worth highlighting that nearly 440 patents have been filed / granted, since 2001, for single-use downstream bioprocessing technologies and equipment..   

Request for Customization @ https://www.rootsanalysis.com/reports/single-use-downstream-bioprocessing-market/request-customization.html

Future of Single-use Downstream Bioprocessing Equipment

Driven by encouraging patent filing efforts, new pharma entrants, broadening of disease focus, and a rising desire to get beyond existing stainless-steel equipment with some innovative ways that could decrease prices and address risk of cross contamination along with high productivity, the single-use equipment are expected to capture a significant share in the biopharmaceutical market with more developers developing productive disposable downstream equipment over the coming decade.

Concluding Remarks

Device developers are actively making efforts to introduce several technical and qualitative features in single-use downstream devices to make them efficient for use, contamination free and disposal. In almost all these equipment, such as single-use chromatography systems, filtration systems, sampling systems, centrifugation systems and connectors, the developers have taken care of sterility. Autoclaving and irradiation (gamma or x-ray) features are must for such equipment, manufacturing life-saving biologics.

The industry is constantly evolving in the space of single-use technology with emergence of more convenient and scalable systems. As the number of commercially available biologics increase, the need for novel manufacturing equipment is also expected to elevate.

The historical trends of the existing single-use upstream bioprocessing equipment, such as single-use bioreactors, suggest a strong demand in the market. The single-use downstream bioprocessing equipment market is expected to follow a similar growth trend as more developers shift from conventional to user-friendly, high quality, scalable, disposable biopharmaceutical manufacturing alternatives.

Request for Sample: https://www.rootsanalysis.com/reports/single-use-downstream-bioprocessing-market/request-sample.html

 

Read Our Latest Press Release:

https://www.rootsanalysis.com/blog/myeloid-cell-targeting-therapeutics-budding-therapy-against-cancer-2/

https://www.rootsanalysis.com/blog/site-management-organizations-a-deeper-look-into-clinical-trial-site-management-landscape/

https://www.rootsanalysis.com/blog/at-home-blood-collection-new-era-of-diagnosis-and-testing/

https://www.rootsanalysis.com/blog/myeloid-cell-targeting-therapeutics-budding-therapy-against-cancer/

https://www.rootsanalysis.com/blog/regulatory-t-cell-therapies-a-research-hotspot-in-the-field-of-immunotherapy/

 

 

Visit for More Insights: https://www.rootsanalysis.com/reports.html

Read Our Latest Press Release: https://www.rootsanalysis.com/press-releases.html

Latest Blogs On Healthcare Industry: https://www.rootsanalysis.com/blog/

 

Our Service Portfolio: Pipeline Tracking | Publication Analysis | Investment Analysis | Market Assessment | Competitive Profiling | Commercial Strategy and Business Development 

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.

Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

bitterlime

Angry Lime

bitterlime - 一个月前

Today, I'm not bitter. Better yet, I'm angry. 
Have you comically imagine an angry lime?
Wait, so is it yellow, green or ... the unimaginable red?

Wouldn't that make me a tomato?

Temper has always been the ghastly awful horrible (more negative) side of me.
It always never fails to topple my outlook of a cool cucumber persona whenever things get out of hand or rather, the other party is being condescending.

I love greatly, loyally, and that said, I protect love aggressively.
So what happens when love betrays?
Can you please give a "Royal Albert Hall's" space to just think about if THAT happened to me. The whole building would have been burnt down coupled with a devastating earthquake. 

 

Well, folks. THAT did happened to me and safe to say, nothing happened. 

No burnt building, no earthquake.

Yup, nada. 

 

And you know what happened? 

 

Life. 

 

Hence the angry lime, for now.

搜索交友社区

我是
对象
作为
年龄 to
国家
州/区域
  • 正在线上
  • 附照片
  • 藏图库
  • 安全性行为
  • New

精选个人档案

Now ALL members can view unlimited profiles!

Languages

View this page in a different language:

赞好

合作伙伴

 ILGA Asia - Fridae partner for LGBT rights in Asia IGLHRC - Fridae Partner for LGBT rights in Asia

Advertisement